CBPO earnings call for the period ending March 31, 2020.
News & Analysis: China Biologic Products
After receiving two buyout offers this summer, the company forged its own path forward -- one that stuffs the balance sheet with around $590 million.
The blood plasma specialist has received a second buyout offer.
The Chinese plasma manufacturer might be acquired for $110 per share.